CRISPR-Quest Gene Editing Tests
The research community’s rapid acceptance of the CRISPR/Cas9 technology is propelling a stage of deep investment in technology development. Already, three companies have emerged focusing on CRISPR therapeutic applications: Intellia Therapeutics, Editas Medicine, and CRISPR Therapeutics.
CRISPR-Quest Gene Editing Test is based on DiaCarta’s next-generation polymerase chain reaction technology – QClamp®. It provides a rapid, low-cost, ultra-sensitive quantification of both NHEJ- and HDR-editing events to meet the growing need for a screening technology that is generally applicable.
How it works
- Nuclease-induced double-strand breaks (DSBs) can be repaired by one of the two pathways: Non-homologous end joining (NHEJ) and Homology-directed repair (HDR)
- Imprecise NHEJ can produce insertion and/or deletion mutations of variable length at DSB site
- HDR can introduce precise point mutations or insertions from ss- or ds- DNA donor template
Features and Benefits
- Leverage QClamp technology to detect low-frequency HDR and NHEJ editing events
- Suitable for HDR in primary or induced pluripotent stem (iPS) cells
- Enable empirical validation of guide RNA efficiency and measurement of HDR: NHEJ ratio at targeted locus
- Rapid (assay run time < 2 hours)
- Low cost (no capital investment like ddPCR and NGS)
- Ultra sensitive of low-frequency HDR and NHEJ editing events (Platform powered by QClamp®)